# reload+after+2024-01-22 08:47:36.376491
address1§201 Brookline Avenue
address2§Suite 901
city§Boston
state§MA
zip§02215
country§United States
phone§857 320 4900
website§https://www.tangotx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
fullTimeEmployees§110
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Barbara L. Weber M.D.', 'age': 65, 'title': 'President, CEO & Director', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 941162, 'exercisedValue': 0, 'unexercisedValue': 4429561}, {'maxAge': 1, 'name': 'Ms. Daniella  Beckman CPA', 'age': 44, 'title': 'Chief Financial Officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 619129, 'exercisedValue': 0, 'unexercisedValue': 1331724}, {'maxAge': 1, 'name': 'Dr. Alan  Ashworth FRS, Ph.D.', 'age': 62, 'title': 'Founder & Member of Scientific Advisory Board', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Levi  Garraway M.D., Ph.D.', 'age': 54, 'title': 'Founder', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. William G. Kaelin Jr., M.D.', 'age': 65, 'title': 'Founder & Member of Scientific Advisory Board', 'yearBorn': 1958, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Timothy K. Lu M.D., Ph.D.', 'age': 42, 'title': 'Founder', 'yearBorn': 1981, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Antoni  Ribas M.D., Ph.D.', 'age': 56, 'title': 'Founder & Member of Scientific Advisory Board', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jannik N. Andersen Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Douglas J. Barry Esq., J.D.', 'age': 53, 'title': 'General Counsel, Chief Compliance Officer & Corporate Secretary', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John C. Ross M.S.', 'title': 'Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§5
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.942
priceToSalesTrailing12Months§24.962494
currency§USD
dateShortInterest§1702598400
forwardEps§-1.34
exchange§NGM
quoteType§EQUITY
shortName§Tango Therapeutics, Inc.
longName§Tango Therapeutics, Inc.
firstTradeDateEpochUtc§1599139800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§90cada1d-9f83-3886-ad2a-ac647db270d6
gmtOffSetMilliseconds§-18000000
targetHighPrice§20.0
targetLowPrice§16.0
targetMeanPrice§17.33
targetMedianPrice§17.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§6
quickRatio§8.289
grossMargins§-2.01144
ebitdaMargins§-2.86237
trailingPegRatio§None
